In June 2024, SIOP-RTSG and COG RTC ( bridged in the HARMONICA initiative) is hosting the 12th International Biology Meeting for Pediatric Renal Tumors in New York, hosted by Dr Michael Ortiz
Wednesday, June 5, 2024, 9:00 AM – Friday, June 7, 2024, 7:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY
This complimentary symposium at Memorial Sloan Kettering focuses on the biology and clinical translation of emerging research in pediatric renal tumors, particularly Wilms tumor, but also RCC and other rare childhood kidney tumors. The symposium will consist of didactic lectures, poster sessions, as well as focused breakout discussions, the latter being focused on pre-clinical pediatric renal tumor models and prioritizing targets and therapies for advanced Wilms tumors. This large, but focused gathering of scientists, clinicians, and other key stakeholders, will provide significant opportunities for both learning and networking. Please see below for information on the symposium social events.
WEDNESDAY, JUNE 5, will initially begin with an educational overview of pediatric renal tumors before the scientific meeting commencement in order to provide a foundational basis for attendees with varied backgrounds. The afternoon launches the formal symposium with a focus on the renal biological processes, both physiologic and pathologic, that lead to the development of childhood kidney tumors. There will be a particular focus on renal regeneration and repair as well as advances in our understanding of clonal nephrogenesis.
THURSDAY, JUNE 6, will include discussions of advances in our understanding of the genomics, epigenomics, and proteomics of childhood kidney tumors. This will include discussion on topics such as cancer predisposition, clonal evolution, intratumoral heterogeneity, preclinical tumor models, as well as emerging technologies such as circulating tumor DNA.
FRIDAY, JUNE 7, will transition towards more clinically actionable investigations, consisting of talks related to immunotherapy, targeted therapies, and current and emerging clinical trials including novel study designs. There will be a particular focus on rare non-Wilms renal tumors, such as renal cell carcinoma, rhabdoid tumor, and childhood kidney sarcomas.
